Slavic Magic has released a major new update for Manor Lords, its medieval strategy game, with the update adding a new option to choose starting ...

After a brutal drawdown, Vertex is quietly doing the things long-term investors usually say they want and one fund just ...

Wondering whether Vertex Pharmaceuticals is still worth buying at around $452 a share, or if the big gains are already behind ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

Editorial Note: We earn a commission from partner links on Forbes Advisor. Commissions do not affect our editors' opinions or evaluations. Disclaimer: Calculator results and default inputs are ...

Investing.com -- Palo Alto Networks shares rose on Friday after the cybersecurity firm announced an expanded strategic ...

Investing.com -- Google has released Gemini 3 Flash, a new AI model designed to deliver high-level intelligence with faster processing speeds at lower costs.

Shares of Vertex Pharmaceuticals Inc. rose 6.92% to $463.13 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.30% to 6,849.72 ...